<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965949</url>
  </required_header>
  <id_info>
    <org_study_id>HRT001</org_study_id>
    <nct_id>NCT03965949</nct_id>
  </id_info>
  <brief_title>Different Strategies in Frozen IVF/ICSI Cycles</brief_title>
  <official_title>Impact of Different Strategies in Frozen Cycles Using HRT in Normo Responding Patients Undergoing IVF/ICSI Cycles: a Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Democritus University of Thrace</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the absence of robust contemporary data, investigators decided to perform a multicenter&#xD;
      cohort study of various IVF centers, to compare the different modalities used for pregnancy&#xD;
      rates following frozen-thawed embryo transfer (FET) treatment cycles in normoovulatory&#xD;
      patients undergoing IVF/ICSI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general, the type of FET protocol for each patient is selected by the attending physicians&#xD;
      at their own discretion. In all centers, patients with ovulatory cycles are typically&#xD;
      prescribed an NC-FET or mNC-FET, whereas patients with oligomenorrhoea or amenorrhoea are&#xD;
      prescribed an artificial cycle to prepare the endometrium for FET.&#xD;
&#xD;
      Ovarian stimulation protocol&#xD;
&#xD;
        1. The antagonist protocol&#xD;
&#xD;
        2. The long 21 /2 agonist protocol Laboratory technique&#xD;
&#xD;
      a. IVF or b. ICSI Embryo freezing using only vitrification will be performed in days 3 or&#xD;
      5/6. Embryo transfer will be conducted at days 3 or 5/6. The maximum number of embryos&#xD;
      transferred will be two, as in accordance to the Hellenic legislation.&#xD;
&#xD;
      The following modalities will be analyzed, patients with:&#xD;
&#xD;
        1. Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without&#xD;
           luteal support (Group 1)&#xD;
&#xD;
        2. Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with&#xD;
           luteal support (progesterone) (Group 2)&#xD;
&#xD;
        3. Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support&#xD;
           (progesterone) (Group 3)&#xD;
&#xD;
        4. Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support&#xD;
           (progesterone) (Group 4)&#xD;
&#xD;
      Of note, the conversion between different supplementation methods may be testimated as&#xD;
      follows: 0.75 mg of micronised estradiol (oral administration) = 1.25 g of estradiol gel&#xD;
      (transdermal administration) = 1 mg of estradiol valerate (oral or vaginal adminstration).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Actual">December 2, 2019</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>live birth</measure>
    <time_frame>1 year</time_frame>
    <description>birth after 20 weeks of gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ongoing pregnancy</measure>
    <time_frame>3 months</time_frame>
    <description>positive heart rate after 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miscarriage</measure>
    <time_frame>6 months</time_frame>
    <description>pregnancy loss up to 20 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical pregnancy (positive β-hCG), multiple, ectopic and clinical pregnancy rates</measure>
    <time_frame>3 months</time_frame>
    <description>positive β-hCG, multiple, ectopic and clinical pregnancy rates</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">311</enrollment>
  <condition>Pregnancy Rates</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement cycle 1</intervention_name>
    <description>Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement cycle 2</intervention_name>
    <description>Hormone Replacement cycle with GnRHa suppression</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Following clinical evaluation along with previous medical and reproductive history,&#xD;
        participants will be categorized according to the subfertility factor and further&#xD;
        demographic parameters (age, Body Mass Index (BMI), smoking status, basal FSH levels,&#xD;
        parity, antral follicle count (AFC) in the fresh cycle, type (primary/secondary) and&#xD;
        duration of subfertility and number of unsuccessful IVF/ICSI attempts (fresh and/or frozen)&#xD;
        will be recorded along with the respective hormonal profiles.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        age 25-39 years, BMI ≤ 35 and ≥ 19, normo-ovulatory patients and basal FSH ≤11 mIU/mL.&#xD;
        Definition of expected normal ovarian response will be based primarily on antral follicle&#xD;
        count (AFC) between 6-14.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        history of more than three previous unsuccessful IVF/ICSI cycles, FSH &gt; 12 mIU/mL, BMI &gt;35&#xD;
        or &lt;19, poor ovarian response according to the 2011 Bologna criteria, PCOS patients&#xD;
        according to the Rotterdam criteria, history of untreated autoimmune, endocrine or&#xD;
        metabolic disorders, history of pathology affecting the endometrial cavity and/or&#xD;
        receptivity and clinical and/or laboratory markers of hereditary or acquired thrombophilia&#xD;
        that complied to the standard protocols of each Unit and patients without embryo after&#xD;
        thawing.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Obstetrics Gynaecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will discuss it with other authors</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

